Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
Quipt Home Medical (NASDAQ: QIPT) reported its fiscal Q3 2025 results, showing signs of stabilization with a return to positive quarter-over-quarter organic growth of 1.6%. Revenue reached $58.3 million, down 4.1% year-over-year, while Adjusted EBITDA was $13.7 million (23.5% of revenue).
The company maintained strong recurring revenue at 81% of total revenue and served 151,000 unique patients. Post-quarter, Quipt acquired a DME provider from Ballad Health for $6.6 million in annual revenue, expanding its presence across four branch locations and securing a Preferred Provider Agreement with access to 20 hospitals.
Despite posting a net loss of ($3.0 million), the company maintains a healthy balance sheet with a Net Debt to Adjusted EBITDA leverage ratio of 1.5x and total credit availability of $35.3 million.
Quipt Home Medical (NASDAQ: QIPT) ha riportato i risultati del terzo trimestre fiscale 2025, mostrando segnali di stabilizzazione con un ritorno alla crescita organica trimestre su trimestre positiva dell'1.6%. I ricavi hanno raggiunto $58.3 million, in calo del 4.1% su base annua, mentre l'EBITDA rettificato 猫 stato di $13.7 million (23.5% dei ricavi).
L'azienda ha mantenuto forti ricavi ricorrenti pari al 81% del totale e ha servito 151,000 pazienti unici. Dopo il trimestre, Quipt ha acquisito da Ballad Health un fornitore di DME con ricavi annui di $6.6 million, espandendo la propria presenza su quattro sedi e assicurandosi un Accordo di Fornitore Preferenziale con accesso a 20 ospedali.
Nonostante una perdita netta di ($3.0 million), la societ脿 mantiene un bilancio solido con un rapporto debito netto su EBITDA rettificato di 1.5x e una disponibilit脿 di credito totale di $35.3 million.
Quipt Home Medical (NASDAQ: QIPT) present贸 sus resultados del tercer trimestre fiscal 2025, mostrando signos de estabilizaci贸n con un regreso al crecimiento org谩nico intertrimestral positivo del 1.6%. Los ingresos alcanzaron $58.3 million, una ca铆da del 4.1% interanual, mientras que el EBITDA ajustado fue de $13.7 million (23.5% de los ingresos).
La compa帽铆a mantuvo ingresos recurrentes s贸lidos que representaron el 81% del total y atendi贸 a 151,000 pacientes 煤nicos. Tras el trimestre, Quipt adquiri贸 a Ballad Health un proveedor de DME con ingresos anuales de $6.6 million, ampliando su presencia a cuatro sucursales y asegurando un Acuerdo de Proveedor Preferente con acceso a 20 hospitales.
A pesar de registrar una p茅rdida neta de ($3.0 million), la empresa mantiene un balance sano con una ratio Deuda Neta a EBITDA Ajustado de 1.5x y una disponibilidad total de cr茅dito de $35.3 million.
Quipt Home Medical (NASDAQ: QIPT)電� 2025 須岅硠鞐半弰 3攵勱赴 鞁れ爜鞚� 氚滍憸頃橂┌ 攵勱赴 旮办 鞙犼赴鞝� 靹膘灔毳犾澊 雼れ嫓 1.6%搿� 頂岆煬鞀� 鞝勴櫂霅橂姅 霌� 鞎堨爼頇� 鞁犿樃毳� 氤挫榾鞀惦媹雼�. 毵れ稖鞚� $58.3 million鞙茧 鞝勲厔 雽�牍� 4.1% 臧愳唽頄堦碃, 臁办爼 EBITDA電� $13.7 million (毵れ稖鞚� 23.5%)鞚� 旮半頄堨姷雼堧嫟.
須岇偓電� 鞝勳泊 毵れ稖鞚� 81%毳� 彀頃橂姅 瓴“頃� 氚橂车 毵れ稖鞚� 鞙犾頄堨溂氅�, 151,000氇呾潣 瓿犾湢 頇橃瀽鞐愱矊 靹滊箘鞀るゼ 鞝滉车頄堨姷雼堧嫟. 攵勱赴 鞚错泟 Quipt電� Ballad Health搿滊秬韯� 鞐瓣皠 毵れ稖 $6.6 million 攴滊鞚� DME 鞝滉车鞐呾泊毳� 鞚胳垬頃� 4臧� 歆�鞝愳溂搿� 鞛呾毳� 頇曤寑頃橁碃 20臧� 氤戩洂鞐� 鞝戧芳 臧�電ロ暅 鞖办劆 瓿店笁鞛� 瓿勳暯鞚� 頇曤炒頄堨姷雼堧嫟.
($3.0 million)鞚� 靾滌啇鞁れ潉 旮半頄堨潓鞐愲弰 攵堦惮頃橁碃, 須岇偓電� 靾滊秬毂� 雽�牍� 臁办爼 EBITDA 霠堧矂毽 牍勳湪 1.5氚办檧 齑� 鞁犾毄 臧�鞖╈暋 $35.3 million鞙茧 瓯挫爠頃� 鞛甑“毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟.
Quipt Home Medical (NASDAQ: QIPT) a publi茅 ses r茅sultats du troisi猫me trimestre fiscal 2025, montrant des signes de stabilisation avec un retour 脿 une croissance organique trimestre sur trimestre positive de 1.6%. Le chiffre d'affaires s'est 茅lev茅 脿 $58.3 million, en baisse de 4.1% sur un an, tandis que l'EBITDA ajust茅 s'est 茅tabli 脿 $13.7 million (23.5% du chiffre d'affaires).
L'entreprise a conserv茅 des revenus r茅currents solides repr茅sentant 81% du total et a servi 151,000 patients uniques. Apr猫s la cl么ture du trimestre, Quipt a acquis aupr猫s de Ballad Health un fournisseur de DME g茅n茅rant $6.6 million de revenus annuels, 茅tendant sa pr茅sence 脿 quatre agences et obtenant un accord de fournisseur privil茅gi茅 donnant acc猫s 脿 20 h么pitaux.
Malgr茅 une perte nette de ($3.0 million), la soci茅t茅 conserve un bilan sain avec un ratio dette nette sur EBITDA ajust茅 de 1.5x et une disponibilit茅 totale de cr茅dit de $35.3 million.
Quipt Home Medical (NASDAQ: QIPT) ver枚ffentlichte die Ergebnisse f眉r das Fiskalquartal Q3 2025 und zeigte Anzeichen einer Stabilisierung mit einer R眉ckkehr zu positivem organischen Wachstum gegen眉ber dem Vorquartal von 1.6%. Der Umsatz belief sich auf $58.3 million, ein R眉ckgang von 4.1% im Jahresvergleich, w盲hrend das bereinigte EBITDA $13.7 million (23.5% des Umsatzes) betrug.
Das Unternehmen hielt einen hohen Anteil wiederkehrender Erl枚se von 81% am Gesamtumsatz und betreute 151,000 einzelne Patienten. Nach Quartalsende erwarb Quipt von Ballad Health einen DME-Anbieter mit einem Jahresumsatz von $6.6 million, erweiterte damit seine Pr盲senz auf vier Standorte und sicherte sich eine Preferred-Provider-Vereinbarung mit Zugang zu 20 Krankenh盲usern.
Trotz eines ausgewiesenen Nettoverlusts von ($3.0 million) verf眉gt das Unternehmen 眉ber eine gesunde Bilanz mit einem Verschuldungsgrad Nettofinanzverbindlichkeiten zu bereinigtem EBITDA von 1.5x und einer gesamten Kreditverf眉gbarkeit von $35.3 million.
- Return to positive quarter-over-quarter organic growth of 1.6%
- Strong Adjusted EBITDA margin at 23.5% of revenue
- Robust recurring revenue at 81% of total revenue
- Strategic acquisition of Ballad Health DME provider with $6.6M annual revenue
- Increased cash flow from operations to $27.9M, up from $25.4M year-over-year
- Conservative leverage ratio of 1.5x Net Debt to Adjusted EBITDA
- Secured Preferred Provider Agreement with access to 20 hospitals
- Revenue declined 4.1% year-over-year to $58.3M
- Net loss increased to ($3.0M) from ($1.6M) year-over-year
- Customer base decreased 1.3% year-over-year
- Cash on hand reduced to $11.3M from $17.1M in previous quarter
- Adjusted EBITDA decreased 3.6% year-over-year
Insights
Quipt shows operational improvement with return to positive organic growth despite year-over-year revenue decline; strategic acquisition strengthens healthcare system partnerships.
Quipt's Q3 2025 results present a mixed but stabilizing picture. While revenue decreased
The company maintained healthy profitability with Adjusted EBITDA margins of
Notably, operational metrics show improvement on a sequential basis with patient count increasing 3.4% quarter-over-quarter to 151,000 and respiratory resupply set-ups growing
The strategic acquisition of Ballad Health's DME business appears financially prudent, adding
Posts Positive Organic Growth and Adjusted EBITDA鈥�1 of
CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (鈥�Quipt鈥� or the 鈥�Company鈥�) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal third quarter 2025 financial results and operational highlights. These results pertain to the three and nine months ended June 30, 2025, and are reported in United States dollars.
Conference Call
Quipt will host its Earnings Conference Call on Tuesday, August 12, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (833) 752-3722 or 1 (647) 846-8549.
A live webcast of the call will be accessible via the investor section of the Company鈥檚 website through the following link: , and a replay will be available on the investor section of the Company鈥檚 website for at least the first year following the event.
Financial Highlights:
- Revenue for Q3 2025 was
$58.3 million compared to$60.8 million for Q3 2024, representing a4.1% decrease. This compares to revenue of$57.4 million in Q2 2025, reflecting a return to positive quarter-over-quarter organic growth of1.6% . - Revenue for the nine months ended June 30, 2025 decreased to
$177.0 million , compared to$184.6 million for the nine months ended June 30, 2024, representing a decrease of4.1% . - Recurring Revenue鈥�1听for Q3 2025 continues to be strong at
81% of total revenue. - Adjusted EBITDA1听for Q3 2025 was
$13.7 million (23.5% of revenue) compared to$14.2 million (23.4% of revenue) for Q3 2024, representing a3.6% decrease. - Adjusted EBITDA1 of
$41 million (23.2% of revenue) for the nine months ended June 30, 2025, compared to$44.4 million (24.1% of revenue) for the nine months ended June 30, 2024, a decrease of7.7% . - Net income (loss) for Q3 2025 was (
$3.0) million , or ($0.07) per diluted share, compared to ($1.6) million , or ($0.04) per diluted share, for Q3 2024. - Cash flow from operations was
$27.9 million for the nine months ended June 30, 2025, compared to$25.4 million for the nine months ended June 30, 2024. - The Company reported
$11.3 million of cash on hand as of June 30, 2025 as compared to$17.1 million of cash on hand as of March 31, 2025. Total credit availability of$35.3 million as of June 30, 2025, with$14.3 million available on a revolving credit facility and$21.0 million available pursuant to a delayed-draw term loan facility. - The Company maintains a conservative balance sheet with Net Debt to Adjusted EBITDA Leverage Ratio1听of 1.5x.
Operational Highlights:
- The Company鈥檚 customer base decreased
1.3% year-over-year, serving 151,000 unique patients as of June 30, 2025, compared to 153,000 unique patients as of June 30, 2024. This compares to 146,000 in Q2 2025, reflecting a positive quarter-over-quarter growth of3.4% . - Completed 210,000 unique set-ups/deliveries in Q3 2025, a
2.8% decrease from 216,000 set-ups/deliveries in Q3 2024. This compares to 203,000 in Q2 2025, reflecting a positive quarter-over-quarter growth of3.5% . - Respiratory resupply set-ups/deliveries were 119,000 in Q3 2025, compared to 120,000 in Q3 2024. This compares to 111,000 in Q2 2025, reflecting a positive quarter-over-quarter growth of
7.2% .
Subsequent Highlights:
- On July 7th, 2025, Quipt announced the acquisition of
100% of a full-service durable medical equipment (DME) provider, which was wholly-owned by Ballad Health, a major integrated health system serving the Appalachian Highlands region.- The acquiree reported unaudited revenue of
$6.6 million for the fiscal year ended June 30, 2025. - The acquisition expanded Quipt's reach to over 12,500 patients annually across four branch locations in East Tennessee and Southwest Virginia.
- Quipt also signed a Preferred Provider Agreement (PPA) with Ballad Health embedding the Company directly into the health system's hospital discharge planning process and providing access to patient referrals from 20 hospitals across Tennessee, Virginia, North Carolina, and Kentucky.
- The transaction was funded entirely with cash on hand and at a highly attractive valuation, preserving balance sheet flexibility.
- Management expects the acquired operation's Adjusted EBITDA margins to align with Quipt's historical range within two quarters, driven by operational efficiencies and clinical workflow integration.
- The acquiree reported unaudited revenue of
Management Commentary:
鈥淥ur third quarter results reflect important progress, as we returned to positive organic growth and achieved clear revenue stabilization across the overall business. These results highlight the dedication of our team and the structural improvements we鈥檝e made over the past several quarters, which position us for sustainable long-term growth,鈥� said Greg Crawford, Chief Executive Officer and Chairman of Quipt.
鈥淭he subsequent completion of the Ballad Health acquisition marks a meaningful milestone for Quipt. This transaction embeds us directly into the discharge pathway of a prominent integrated health system and reinforces our broader strategy of expanding through healthcare system partnerships. We believe this scalable model will be powerful in advancing our growth platform.
As we move through the remainder of 2025 and into 2026, our focus remains on maximizing long-term shareholder value. The Board and management team continue to evaluate opportunities supporting this objective and we are confident the actions we are taking today will lay a strong foundation for future value creation.鈥�
鈥淲e are extremely pleased with the stability we saw in our fiscal third quarter results. Our Adjusted EBITDA margin remained strong and consistent, even as we have navigated a transitioning revenue environment. This underscores the scalability and resiliency of our operating platform,鈥� said Hardik Mehta, Chief Financial Officer of Quipt. 鈥淲e are thrilled to have executed the Ballad-owned durable medical equipment acquisition after quarter end while maintaining a conservative balance sheet and strong financial flexibility. This transaction enhances our geographic footprint, deepens our health system relationships, and aligns with our playbook for growth. As we continue to scale, the combination of our recurring revenue base, financial strength, and proven execution gives us confidence in delivering consistent performance.鈥�
1 Non-GAAP financial measure or ratio. See 鈥淣on-GAAP Financial Measures鈥� below for additional information.
ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company鈥檚 organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient鈥檚 services, and making life easier for the patient.
Reader Advisories
Readers are cautioned that the financial information regarding the acquiree disclosed herein is unaudited and derived as a result of听the Company鈥檚 due diligence, including a review of the acquisition鈥檚 bank statements and tax returns.
Forward-Looking Statements
Certain statements contained in this press release constitute 鈥渇orward-looking statements鈥� within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 鈥渇orward-looking information鈥� as such term is 鈥庘�庘�庘�庘�庘�巇efined in applicable Canadian securities legislation (collectively, 鈥渇orward-looking statements鈥�). The words 鈥渕ay鈥�, 鈥渨ould鈥�, 鈥渃ould鈥�, 鈥渟hould鈥�, "potential鈥�, 鈥庘�庘�庘�庘�庘�庘��"will鈥�, "seek鈥�, "intend鈥�, 鈥減lan鈥�, 鈥渁nticipate鈥�, 鈥渂elieve鈥�, 鈥渆stimate鈥�, 鈥渆xpect鈥�, 鈥渙utlook鈥�, or the negatives thereof or variations of such words, and similar expressions 鈥庘�庘�庘�庘�巃s 鈥巘hey relate to the Company are intended to 鈥巌dentify forward-looking statements, including: the Company anticipating strong margin performance throughout the year and a return to historical organic growth levels in calendar 2025; the Company鈥檚 expectations regarding the impact of the acquisition of the DME provider and the PPA; management鈥檚 expectations regarding the acquiree鈥檚 Adjusted EBITDA margin and the timing of such results; and opportunities to increase long-term shareholder value. All statements 鈥巓ther 鈥巘han 鈥巗tatements of 鈥庘�巋istorical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-鈥巐ooking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the 鈥嶤ompany's 鈥巆urrent 鈥巚iews and 鈥庘�巌ntentions with respect to future 鈥巈vents, and current information available to the 鈥嶤ompany, and 鈥巃re 鈥巗ubject to 鈥庘�巆ertain risks, uncertainties and 鈥巃ssumptions, including, without limitation: the 鈥嶤ompany successfully identifying, 鈥庘�庘�巒egotiating and 鈥巆ompleting additional acquisitions; operating and other financial metrics maintaining their 鈥庘�巆urrent trajectories, the Company not being impacted by any further external and unique events like the Medicare 鈥庘��75/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of 2025; and the 鈥嶤ompany not being subject to a material change to it cost structure. Many 鈥巉actors could cause the actual 鈥巖esults, 鈥庘�巔erformance or achievements that may be 鈥巈xpressed 鈥巓r implied by such 鈥巉orward-looking statements to 鈥巚ary from 鈥庘�巘hose described herein should one or more 鈥巓f these 鈥巖isks or 鈥巙ncertainties materialize. Examples of such 鈥巖isk 鈥巉actors 鈥巌nclude, without limitation: risks related 鈥巘o credit, market 鈥庘�庘��(including equity, commodity, foreign exchange 鈥巃nd interest 鈥巖ate), 鈥巐iquidity, operational 鈥庘��(including technology 鈥巃nd 鈥巌nfrastructure), reputational, insurance, 鈥巗trategic, 鈥巖egulatory, legal, 鈥巈nvironmental, and 鈥巆apital adequacy; the 鈥庘�巊eneral business and economic conditions in 鈥巘he regions 鈥巌n which the 鈥嶤ompany operates; 鈥巘he ability of the 鈥庘�嶤ompany to execute on key priorities, including the 鈥巗uccessful 鈥巆ompletion of 鈥巃cquisitions, 鈥巄usiness retention, and 鈥庘�巗trategic plans and to attract, develop and retain 鈥巏ey 鈥巈xecutives; difficulty 鈥巌ntegrating 鈥巒ewly acquired businesses; 鈥庘�巘he ability to implement business strategies and 鈥庘�巔ursue business opportunities; low 鈥巔rofit 鈥巑arket segments; 鈥庘�巇isruptions in or attacks (including cyber-attacks) on 鈥庘�巘he Company's information 鈥巘echnology, 鈥巌nternet, network 鈥庘�巃ccess or other voice or data communications systems or 鈥庘�巗ervices; the evolution of 鈥巚arious types 鈥巓f fraud or other 鈥庘�巆riminal behavior to which the Company is exposed; the 鈥庘�巉ailure of third parties to 鈥巆omply with 鈥巘heir obligations to 鈥庘�巘he Company or its affiliates; the impact of new and 鈥庘�巆hanges to, or application of, 鈥巆urrent 鈥巐aws and regulations; 鈥庘�巇ecline of reimbursement rates; dependence on few 鈥庘�巔ayors; possible new drug 鈥巇iscoveries; a 鈥巒ovel business 鈥巑odel; 鈥巇ependence on key suppliers; granting of permits 鈥庘�巃nd licenses in a highly 鈥巖egulated 鈥巄usiness; legal proceedings and litigation, including as it relates to the civil 鈥庘�巌nvestigative demand (鈥淐ID鈥�) 鈥巖eceived from the Department of Justice; 鈥巌ncreased competition; 鈥巆hanges in 鈥巉oreign currency rates; 鈥巘he imposition of trade restrictions such as tariffs and retaliatory counter measures; increased 鈥庘�巉unding costs and market volatility due to 鈥巑arket illiquidity and 鈥巆ompetition for 鈥巉unding; the 鈥巃vailability of funds 鈥庘�巃nd resources to pursue operations; 鈥巆ritical accounting 鈥巈stimates and changes 鈥巘o accounting 鈥巗tandards, policies, 鈥庘�巃nd methods used by the Company; the Company鈥檚 status as an emerging growth company and a smaller reporting company; the occurrence of 鈥巒atural and unnatural 鈥巆atastrophic 鈥巈vents or health epidemics or concerns; as well as those risk factors 鈥巇iscussed or 鈥庘�巖eferred to 鈥巌n the Company鈥檚 disclosure 鈥巇ocuments filed with 鈥嶶nited States Securities and Exchange 鈥嶤ommission 鈥� and 鈥巃vailable at www.sec.gov, including the Company鈥檚 most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with 鈥巘he securities 鈥巖egulatory authorities in certain provinces of 鈥嶤anada and 鈥庘�庘�巃vailable at www.sedarplus.com. Should any 鈥巉actor affect 鈥巘he Company in an unexpected manner, or 鈥巗hould 鈥庘�庘�巃ssumptions underlying the forward-looking 鈥巗tatement prove 鈥巌ncorrect, the actual results or events may 鈥巇iffer 鈥庘�庘�巑aterially from the results or events predicted. 鈥嶢ny such forward-鈥巐ooking statements are expressly qualified 鈥巌n their 鈥庘�庘�巈ntirety by this cautionary statement. Moreover, 鈥巘he Company 鈥巇oes not assume responsibility for the 鈥巃ccuracy or 鈥庘�庘�巆ompleteness of such forward-looking 鈥巗tatements. The 鈥巉orward-looking statements included in this 鈥巔ress release are made as of the date of this press 鈥巖elease and the 鈥嶤ompany undertakes no obligation to publicly 鈥巙pdate or revise 鈥庘�庘�巃ny forward-looking statements, 鈥巓ther than as 鈥巖equired by applicable law鈥�.鈥�
Non-GAAP Financial Measures
This press release refers to 鈥淎djusted EBITDA鈥�, 鈥淩ecurring Revenue鈥�, and 鈥淣et Debt to Adjusted EBITDA Leverage Ratio鈥�, which are non-GAAP financial measures that do not have standardized meanings prescribed by generally accepted accounting principles in the United States (鈥淕AAP鈥�). The 鈥嶤ompany鈥檚 presentation of these financial measures may not be comparable to similarly titled measures used by 鈥巓ther companies. These financial measures are intended to provide additional information to investors concerning 鈥巘he Company鈥檚 performance.鈥�
Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision for income taxes, certain professional fees, including those related to the CID, the loss of private issuer status, and proxy contests and other actions of activist shareholders, stock-based compensation, acquisition-related costs, change in fair value of derivative liability 鈥� interest rate swaps, gain on disposals of property and equipment, loss (gain) on foreign currency transactions, and share of loss in equity method investment. The following table shows our non-GAAP measure, Adjusted EBITDA, reconciled to our GAAP net loss for the 鈥巉ollowing indicated periods鈥� (in $millions)鈥�:鈥�
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | Three | 听 | Three | 听 | Nine | 听 | Nine | ||||||||
| 听 | months | 听 | months | 听 | months | 听 | months | ||||||||
| 听 | ended听June | 听 | ended听June | 听 | ended听June | 听 | ended听June | ||||||||
| 听 | 30,听2025 | 听 | 30,听2024 | 听 | 30,听2025 | 听 | 30,听2024 | ||||||||
| Net loss | $ | (3.0 | ) | 听 | $ | (1.6 | ) | 听 | $ | (7.2 | ) | 听 | $ | (3.8 | ) |
| Add back: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Depreciation and amortization | 听 | 11.2 | 听 | 听 | 听 | 11.1 | 听 | 听 | 听 | 33.6 | 听 | 听 | 听 | 33.0 | 听 |
| Interest expense, net | 听 | 1.5 | 听 | 听 | 听 | 1.6 | 听 | 听 | 听 | 4.6 | 听 | 听 | 听 | 4.9 | 听 |
| Right-of-use operating lease amortization and interest | 听 | 1.6 | 听 | 听 | 听 | 1.7 | 听 | 听 | 听 | 4.8 | 听 | 听 | 听 | 4.6 | 听 |
| Provision for income taxes | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 0.1 | 听 | 听 | 听 | 0.5 | 听 |
| Professional fees | 听 | 1.3 | 听 | 听 | 听 | 0.7 | 听 | 听 | 听 | 3.1 | 听 | 听 | 听 | 2.2 | 听 |
| Stock-based compensation | 听 | 2.1 | 听 | 听 | 听 | 0.5 | 听 | 听 | 听 | 2.6 | 听 | 听 | 听 | 2.2 | 听 |
| Acquisition-related costs | 听 | 0.1 | 听 | 听 | 听 | 0.2 | 听 | 听 | 听 | 0.2 | 听 | 听 | 听 | 0.4 | 听 |
| Change in fair value of derivative liability - interest rate swaps | 听 | 0.2 | 听 | 听 | 听 | (0.1 | ) | 听 | 听 | (0.4 | ) | 听 | 听 | 0.2 | 听 |
| Gain on disposals of property and equipment | 听 | (0.8 | ) | 听 | 听 | (0.1 | ) | 听 | 听 | (0.9 | ) | 听 | 听 | (0.1 | ) |
| Loss (gain) on foreign currency transactions | 听 | (0.6 | ) | 听 | 听 | 0.1 | 听 | 听 | 听 | 0.2 | 听 | 听 | 听 | 0.1 | 听 |
| Share of loss in equity method investment | 听 | 0.1 | 听 | 听 | 听 | 0.1 | 听 | 听 | 听 | 0.2 | 听 | 听 | 听 | 0.2 | 听 |
| Adjusted EBITDA | $ | 13.7 | 听 | 听 | $ | 14.2 | 听 | 听 | $ | 41.0 | 听 | 听 | $ | 44.4 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
Recurring Revenue for Q3 2025 is calculated as rentals of medical equipment of
Net Debt to Adjusted EBITDA Leverage Ratio is calculated as Net Debt, divided by (Adjusted EBITDA for Q3 times four), and is reconciled as follows (in $millions):
| 听 | 听 | 听 |
| 听 | As of and for the three months ended June 30, 2025 | |
| Senior credit facility, principal | $ | 66.0 |
| Equipment loans | 听 | 10.5 |
| Lease liabilities | 听 | 16.9 |
| Cash | 听 | (11.3) |
| Net Debt | $ | 82.1 |
| Adjusted EBITDA for Q3 times four | $ | 54.8 |
| Net Debt to Adjusted EBITDA Leverage Ratio | 听 | 1.5x |
For further information please visit our website at www.Quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
FAQ
What were Quipt Home Medical's (QIPT) Q3 2025 earnings results?
How much recurring revenue does Quipt Home Medical generate?
What acquisition did Quipt Home Medical complete in July 2025?
What is Quipt Home Medical's current financial position?
How many patients does Quipt Home Medical serve?
